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blood pressure control. The aim of this prospective study was to com-
pare the magnitude of the effects on renal function and blood pressure
control in CKD and non-CKD patients with controlled hypertension
(CHT) vs. uncontrolled hypertension (UHT).
We conducted a prospective, longitudinal study of 187 hypertensive
subjects, being 60 CKD CHT, 48 CKD UHT, 37 non-CKD CHT, and 42 non-Hypertension remains a major global public health burden, leading
attributed cause of mortality worldwide [1]. Every 20/10-mm Hg in-
crease in blood pressure (BP) is associatedwith a doubling of cardiovas-
cular mortality [2,3]. Epidemiological studies have shown that
awareness of this disease is low, with only half of hypertensives ade-
quately treated to target BP levels [4–6]. Nowadays, out-of-ofﬁce BP is
an important adjuvantmethod to be associatedwith conventional ofﬁce
BP measurement, but this last one currently continues to be the most
important tool for hypertension screening, diagnosis, and treatment. Of-
ﬁce BP was enshrined over time. However, this method has important
limitations, which have led to the increasingly frequent suggestion
that 24-hour ambulatory blood pressure measurements (ABPM) play
an important role in hypertensionmanagement [7]. Hypertension is de-
ﬁned as mean systolic BP levels ≥130 mm Hg and/or diastolic BP
≥80 mm Hg in 24-hour ABPM [7].
Sympathetic hyperactivity is well known to increase cardiovascular
risk in chronic kidney disease (CKD) patients and is a hallmark of an es-
sential hypertensive state that occurs early in the clinical course of the
disease [8–10]. In both conditions, hypertension and kidney failure,
the mechanisms of hyperadrenergic state are varied and include reﬂex
and neurohumoral pathways [8,9,11]. In CKD, the sympathetic hyperac-
tivity seems to be expressed at the earliest clinical stage of the disease,
showing a direct relationship with the severity of the condition of
renal impairment [12–15]. The interruption of sympathetic hyperactiv-
ity and feedback of the renin–angiotensin–aldosterone system cycle can
at least partly be beneﬁcial for this population. Based on these patho-
physiological mechanisms, renal sympathetic denervation (RSD) in- Centro, São Gonçalo – Rio de
i).
land Ltd. This is an open access articlCKD and hypertensive patients may ameliorate renal function and
CKD UHT patients. The study was conducted in accordance with the
Helsinki Declaration and approved by the local ethics committee. All pa-
tients gave written informed consent before inclusion. This study was
conducted in the state of Rio de Janeiro, Brazil in the Hospital e Clínica
São Gonçalo. Patients were recruited from June 2012 to January 2016
and were derived from the hospital and the public health network of
the state county. Patients who had the combination of the following
criteria were consecutively enrolled: (i) CHT: mean 24-hour ABPM
b130/b80mmHg; (ii) UHT:mean 24-hour ABPM ≥130/≥80mmHgde-
spite treatment with non-pharmacological measures and use of at least
three antihypertensive drugs (including a diuretic) on maximally toler-
ated doses or conﬁrmed intolerance to medications; (iii) CKD: glomer-
ular ﬁltration rate estimated by the CKD-EPI (Chronic Kidney Disease
Epidemiology Collaboration) equation, eGFR [16], N60 mL/min/
1.73 m2 between 15 and 89 mL/min/1.73 m2 (patients with eGFR
N60 mL/min/1.73 m2 were required to have microalbuminuria); (iv)
non-CKD: glomerular ﬁltration rate estimated by the CKD-EPI (Chronic
Kidney Disease Epidemiology Collaboration) equation, eGFR [16],
N60 mL/min/1.73 m2 (without microalbuminuria); (v) age from 18 to
80 years; and (vi) able to read, understand and sign the informed con-
sent form, and attend clinic visits and exams. Patients with any of the
following criteria were excluded: (i) pregnancy; (ii) valvular heart
disease with signiﬁcant adverse sequelae; (iii) myocardial infarction,
unstable angina, stroke or transient ischemic attack within the previous
six months; (iv) renovascular abnormalities; (v) psychiatric disease;
(vi) allergy to ionic contrast; (vii) inability to be followed clinically
after the procedure; and (viii) serious disease, which in the opinion of
the investigator, may adversely affect the safety and/or efﬁcacy of the
participant or the study.
The 24-hour ABPM [17] and the renal sympathetic denervation are
previously described [18] by our group.
The results were expressed as the mean and standard deviation
(mean ± SD) of the mean in the case of normal distribution and ase under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
General features of patients at baseline.
Parameters CKD CHT CKD UHT Non-CKD CHT Non-CKD UHT Overall P-value
N 60 48 37 42 –
Age, years 54.2 ± 11.3 57.5 ± 10.2 59.4 ± 15.7 61.0 ± 16.5 0.0657
Body mass index, kg/m2 28.5 ± 6.3 26.8 ± 5.4 28.0 ± 6.4 27.3 ± 5.1 0.4672
Male sex (%) 43 (72%) 31 (65%) 22 (59%) 28 (67%) 0.6561
White ethnicity (%) 46 (77%) 30 (63%) 20 (54%) 30 (71%) 0.1033
Atrial ﬁbrillation 22 (37%) 14 (29%) 14 (38%) 17 (40%) 0.7045
Hypertension 60 (100%) 48 (100%) 37 (100%) 42 (100%) 1.0000
Type 2 diabetes mellitus 35 (58%) 22 (46%) 17 (46%) 21 (50%) 0.5328
Hyperlipidemia 40 (67%) 30 (63%) 24 (65%) 31 (74%) 0.4958
Chronic kidney disease 60 (100%) 48 (100%) 0 (0%) 0 (0%) b0.0001
Stage 2 27 (45%) 20 (42%) – – 0.8455†
Stage 3 20 (33%) 14 (29%) – – 0.6814†
Stage 4 13 (22%) 14 (29%) – – 0.3821†
Creatinine, mg/dL 1.36 ± 0.70⁎ 1.42 ± 0.97⁎ 0.90 ± 0.11⁎ 1.02 ± 0.14⁎ 0.0002
eGFR, mL/min/1.73 m2 58.7 ± 24.8⁎⁎ 55.7 ± 33.0⁎⁎ 93.0 ± 10.0⁎⁎ 82.1 ± 14.6⁎⁎ b0.0001
Albumin:creatinine ratio, mg/g 88.2 ± 33.5⁎⁎ 97.5 ± 30.6⁎⁎ 14.5 ± 8.4⁎⁎ 12.2 ± 6.5⁎⁎ b0.0001
Antihypertensive
ACE-inhibitors/ARB 60 (100%) 48 (100%) 37 (100%) 42 (100%) 1.0000
Diuretics 60 (100%) 48 (100%) 37 (100%) 42 (100%) 1.0000
DHP Ca++ channel blockers 60 (100%) 48 (100%) 27 (73%) 31 (74%) b0.0001
β-Blockers 17 (28%) 31 (65%) 20 (54%) 30 (71%) b0.0001
α-Blockers 9 (15%) 23 (48%) 5 (14%) 22 (52%) b0.0001
Spironolactone 13 (22%) 39 (81%) 12 (32%) 35 (83%) b0.0001
Mean 24-hour ABPM, mm Hg
Systolic 123.5 ± 6.2 158.6 ± 9.6 122.0 ± 4.3 143.4 ± 8.0 b0.0001╪
Diastolic 74.0 ± 4.7 110.6 ± 6.5 73.6 ± 5.4 102.3 ± 4.4 b0.0001╪
Values are expressed asMean± SD; ABPM, ambulatory blood pressuremeasurements; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CKD, chronic kidney dis-
ease; CHT, controlled hypertension;DHP, dihydropyridine; eGFR, estimated glomerular ﬁltration rate; RSD, renal sympathetic denervation; UHT, uncontrolledhypertension. Creatinine: *P
b 0.05 for CKD CHT vs. non-CKD CHT, CKD CHT vs. non-CKDUHT, CKDUHT vs. non-CKD CHT, and CKDUHT vs. non-CKD UHT; eGFR and albumin:creatinine ratio: **P b 0.0001 for CKD CHT
vs. non-CKD CHT, CKD CHT vs. non-CKD UHT, CKD UHT vs. non-CKD CHT, and CKD UHT vs. non-CKD UHT. CKD stages: †comparison between only CKD CHT and CKD UHT; Mean 24-hour
ABPM: ╪P b 0.0001 for all comparisons, except for CKD CHT vs. non-CKD CHT;
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two-sided. Comparisons between two paired values were performed by
the paired t-test in case of Gaussian distribution or, alternatively, by the
Wilcoxon test. Comparisons betweenmore than twopaired valueswere
performed by ANOVA for repeated measures or with Kruskal-Wallis
ANOVA as appropriate complemented by a post hoc test. FrequenciesTable 2
Parameters at 6th month after renal sympathetic denervation.
Variable CKD CHT 6th
month
(n = 60)
P-value CKD CHT
baseline vs. 6th
month
CKD UHT 6th
month
(n = 48)
P-value CK
UHT baselin
6th month
Mean 24-hour ABPM,
mm Hg
Systolic 121.8 ± 8.0 0.1958 134.3 ± 12.5 b0.0001
Diastolic 75.5 ± 4.0 0.0622 86.3 ± 11.2 b0.0001
Creatinine, mg/dL 1.04 ± 0.32 0.0017 0.86 ± 0.24 0.0002
eGFR, mL/min/1.73 m2
(CKD-EPI)
81.3 ± 15.8 b0.0001 94.3 ± 16.1 b0.0001
ACR, mg/g 47.8 ± 24.6 b0.0001 33.8 ± 21.0 b0.0001
Values are presented as mean ± SD; ABPM, ambulatory blood pressure measurements; ACR, al
estimated glomerular ﬁltration rate; UHT, uncontrolled hypertension.
Table 3
Variation (Δ) between groups at 6th month after renal sympathetic denervation.
Comparisons CKD CHT vs. CKD
UHT
CKD CHT vs.
non-CKD CHT
CKD
non
Variables Δ P-value Δ P-value Δ
Mean 24-hour ABPM, mmHg
Systolic −12.5 b0.0001 0.2 0.9995 −0.
Diastolic −10.8 b0.0001 1.5 0.7971 −9.
Creatinine, mg/dL 0.18 0.0016 0.12 0.0979 0.08
eGFR, mL/min/1.73 m2 (CKD-EPI) −13 b0.0001 −10.8 0.0018 −4.
ACR, mg/g 14 0.0022 34.1 b0.0001 36.6
Values are presented as variation (Δ) betweenmeans; ABPM, ambulatory blood pressure meas
pertension; eGFR, estimated glomerular ﬁltration rate; UHT, uncontrolled hypertension.were compared with Fisher's Exact Test. P-values b 0.05 were consid-
ered signiﬁcant. Correlations between two variables were performed
by Pearson in the case of Gaussian distribution or, alternatively, with
the Spearman correlation test. All statistical analyses were performed
using the program GraphPad Prism v 7.0 (GraphPad Software, La Jolla,
CA, USA).D
e vs.
Non-CKD CHT 6th
month
(n = 37)
P-value non-CKD
CHT baseline vs.
6th month
Non-CKD UHT 6th
month
(n = 42)
P-value non-CKD
UHT baseline vs.
6th month
121.6 ± 6.1 0.7454 122.4 ± 5.2 b0.0001
74.0 ± 5.9 0.7618 85.4 ± 8.8 b0.0001
0.92 ± 0.19 0.5812 0.96 ± 0.17 0.0812
92.1 ± 10.0 0.6926 85.4 ± 11.8 0.2579
13.7 ± 10.4 0.7665 11.2 ± 9.6 0.5777
bumin:creatinine ratio; CKD, chronic kidney disease; CHT, controlled hypertension; eGFR,
CHT vs.
-CKD UHT
Non-CKD UHT vs.
non-CKD CHT
CKD UHT vs.
non-CKD UHT
Non-CKD CHT vs.
non-CKD UHT
P-value Δ P-value Δ P-value Δ P-value
6 0.9857 12.7 b0.0001 11.9 b0.0001 −0.8 0.9763
9 b0.0001 12.3 b0.0001 0.9 0.9484 −11.4 b0.0001
0.3784 −0.06 0.6857 −0.10 0.2273 −0.04 0.8906
1 0.4709 2.2 0.8911 8.9 0.0164 6.7 0.1531
b0.0001 20.1 b0.0001 22.6 b0.0001 2.5 0.9385
urements; ACR, albumin:creatinine ratio; CKD, chronic kidney disease; CHT, controlled hy-
5M.G. Kiuchi, S. Chen / IJC Heart & Vasculature 13 (2016) 3–5The general features of the 187 hypertensive patients, divided into
60 CKD CHT, 48 CKD UHT, 37 non-CKD CHT, and 42 non-CKD UHT indi-
viduals are listed in Table 1. During the six months of follow-up, the
changes in mean 24-hour ABPM, serum creatinine, eGFR and ACR are
displayed in Table 2. The variation (Δ) between all the comparisons at
the 6th month post RSD for all groups related to the parameters
aforementionated and their respective P values are displayed in Table 3.
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